20/20 Biolabs, Inc. (AIDX)
NASDAQ: AIDX · Real-Time Price · USD
0.2603
-0.0003 (-0.12%)
At close: Oct 19, 2026, 4:00 PM EDT
0.2603
0.00 (0.00%)
After-hours: Oct 19, 2026, 5:49 PM EDT
20/20 Biolabs Revenue
20/20 Biolabs had revenue of $730.57K in the quarter ending June 30, 2026, with 36.54% growth. This brings the company's total for the last twelve months to $2.04M, up 2.73% year-over-year. In the year 2025, 20/20 Biolabs had annual revenue of $2.05M with 16.71% growth. That makes 20/20 Biolabs the 42,341st largest company in the world by revenue and 5,764th in the United States.
Revenue (ttm)
$2.04M
Revenue Growth
+2.73%
P/S Ratio
1.63
Revenue / Employee
$145,729
Employees
14
Market Cap
3.32M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.05M | 292.79K | 16.71% |
| Dec 31, 2024 | 1.75M | 328.04K | 23.03% |
| Dec 31, 2023 | 1.42M | -9.63M | -87.12% |
| Dec 31, 2022 | 11.06M | 1.44M | 14.93% |
| Dec 31, 2021 | 9.62M | 9.35M | 3,373.18% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivos Therapeutics | 20.90M |
| WORK Medical Technology Group LTD | 10.72M |
| INVO Fertility | 7.53M |
| Intelligent Bio Solutions | 4.22M |
| IceCure Medical | 3.95M |
| VolitionRx | 2.46M |
| Co-Diagnostics | 721.39K |
| Adagio Medical Holdings | 137.00K |
AIDX News
- 17 days ago - 20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026 - GlobeNewsWire
- 20 days ago - 20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model - GlobeNewsWire
- 7 weeks ago - 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - GlobeNewsWire
- 7 weeks ago - 20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity - GlobeNewsWire
- 2 months ago - 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level - GlobeNewsWire
- 2 months ago - 20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour - GlobeNewsWire
- 2 months ago - 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy - GlobeNewsWire
- 2 months ago - 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock - GlobeNewsWire